CYV
Ceryvyn Therapeutics Ltd
$0.0110
0.00%
Market cap
$15M
Turnover
$9,761
Last price
$0.0110
Day change
0.00%
Announcements
3
Range, past year
Open 0.013 · Low 0.008 · Now 0.011 · High 0.014
Open CYV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CYV momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
17/100
Wyckoff phase
Accumulation23d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+10.0%
1 Month
+0.0%
RSI
57
Avg daily range
9.9%
Ceryvyn Therapeutics Ltd scores 17 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 23 trading days. The weekly timeframe reads Distribution, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
What stands out
- RSI in healthy zone (57)
Points to watch
- 60d drawdown -30.8%
- High volatility (ATR 9.9%)
- Thin liquidity
- Risk rating: High
- Composite downside risk elevated
CYV announcements
Recent price-sensitive releases.
- 2026-10-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-08-31 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
More Health Care stocks
Most traded in the same sector.